Compare Ascendis Pharma A/S (ASND) vs Lowe`s Companies Inc (LOW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Lowe`s Companies Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Lowe`s Companies Inc trades at $212.03 (market cap $118.66B). The key difference: Lowe`s Companies Inc is far larger — about 6.7× Ascendis Pharma A/S's market cap, and Lowe`s Companies Inc pays a 2.36% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | LOW | |
|---|---|---|
Market Cap | $17.74B | $118.66B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $287.39 |
52-Week Low | $163.32 | $206.62 |
Enterprise Value | $18.11B | $160.42B |
Dividend Yield | — | 2.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Lowe's Companies (LOW) trades at $211.63, down 0.64% on the day, with a bearish technical signal from moving averages. The company maintains solid fundamentals with a P/E of 17.89 and net income margin of 7.51%, having beaten earnings estimates for three consecutive quarters. Revenue declined to $83.67 billion in 2025 but shows stabilization with 2026 projections of $88.4 billion. Analyst consensus remains strongly bullish with a $260.88 price target, representing 23% upside potential from current levels.
LOW presents a compelling value opportunity with strong dividend growth and consistent earnings performance, though near-term headwinds include housing market sensitivity and competitive pressures. The stock's current valuation discount to analyst targets and improving cash flow trends support a positive medium-term outlook, balanced by technical weakness and macroeconomic uncertainties affecting the home improvement sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →
